Results for tag: "Bivalirudin"

Bivalirudin is a cardiovascular drug used to treat and prevent blood clots in patients undergoing coronary angioplasty and other procedures. It is a direct thrombin inhibitor, meaning it works by blocking the action of thrombin, an enzyme involved in the formation of blood clots. Bivalirudin is administered intravenously and is often used in combination with other anticoagulants. It is also used to treat patients with unstable angina and non-ST-segment elevation myocardial infarction. Bivalirudin is a relatively new drug, having been approved by the U.S. Food and Drug Administration in 2000. It has become increasingly popular in recent years due to its efficacy and safety profile. It is also cost-effective compared to other anticoagulants, making it an attractive option for healthcare providers. Several companies are involved in the bivalirudin market, including AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Merck, and Sanofi. These companies manufacture and market bivalirudin-based products, such as Angiomax and Refludan. Show Less Read more